However, the observed outcomes regarding safety profiles showed contrary findings: IO monotherapies showed a trend of similar safety profiles to Sora, whereas combinations of an IO agent with TKI, anti-VEGF, or another IO generally reported significantly higher risks of SAEs, possibly due to enhanced immune activation and overlapping toxicities.
← all excerpts
Updated Network Meta-Analysis of First-Line Systemic Treatments for Advanced HCC: Consistent Role of TACE.
1
—
—